Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Prevention and risk

Topic: Brain proteins, microglia and lab models

Objective Long-term cognitive development is variable among stroke survivors, with a high proportion developing dementia. Early identification of those at risk is highly desirable to target interventions for secondary prevention. Telomere length in peripheral blood mononuclear cells was tested as prognostic risk marker. Methods A cohort of 195 nondemented stroke survivors was followed prospectively from 3 months after stroke for 2 years for cognitive assessment and diagnosis of dementia and for 5 years for survival. Telomere lengths in peripheral blood mononuclear cells were measured at 3 months after stroke by in-gel hybridization. Hazard ratios for survival in relation to telomere length and odds ratios for dementia were estimated using multivariate techniques, and changes in Mini-Mental State Examination scores between baseline and 2 years were related to telomere length using multivariate linear regression. Results Longer telomeres at baseline were associated with reduced risk for death (hazard ratio for linear trend per 1,000 bp = 0.52; 95% confidence interval, 0.28-0.98; p = 0.04, adjusted for age) and dementia (odds ratio for linear trend per 1,000 bp = 0.19; 95% confidence interval, 0.07-0.54; p = 0.002) and less reduction in Mini-Mental State Examination score (p = 0.04, adjusted for baseline score). Interpretation Telomere length is a prognostic marker for poststroke cognitive decline, dementia, and death.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Martin-Ruiz, C., Dickinson, H. O., Keys, B., Rowan, E., Kenny, R. A., & Von Zglinicki, T. (2006). Telomere length predicts poststroke mortality, dementia, and cognitive decline. Annals of neurology. https://doi.org/10.1002/ana.20869

Vancouver

Martin-Ruiz C, Dickinson HO, Keys B, Rowan E, Kenny RA, Von Zglinicki T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Annals of neurology. 2006. doi:10.1002/ana.20869. PMID: 16685698.

BibTeX

@article{martinruiz2006-16685698,
  author  = {Martin-Ruiz, C. and Dickinson, H. O. and Keys, B. and Rowan, E. and Kenny, R. A. and Von Zglinicki, T.},
  title   = {{Telomere length predicts poststroke mortality, dementia, and cognitive decline}},
  journal = {Annals of neurology},
  year    = {2006},
  doi     = {10.1002/ana.20869},
  pmid    = {16685698},
  url     = {https://doi.org/10.1002/ana.20869}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Among non-demented stroke survivors, longer telomeres at baseline were linked to lower risk of death and dementia and less decline in Mini-Mental State Examination scores. This identifies telomere length as a prognostic marker after stroke, not a treatment or cure.

Study details

How this study scored 45/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record left out, no data; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 44 of the 97 points it could be judged on, which is 45 of 100. Total 45 of 100.44 of the 97 points we could judge = 45 of 100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 44 of the 97 points we could judge it on, which is 45 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Annals of neurology)
Journal's citation record 3 / 4 Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2006 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 261 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 11.9 citations a year over 22 year(s) since 2006
Impact for its field and year 3 / 6 Cited 7.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Thomas von Zglinicki: h-index 92 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 16685698)
Free to read 0 / 2 Behind a paywall — scores zero
Points 44 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 44 of the 97 points we could judge it on is 45 out of 100.
Total 45 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Prevention and risk

Also tagged “controlled”

1,118 studies in the library carry the topic tag “controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,118 tagged studies.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →